Quick Answer
Vistagen Therapeutics, Inc. reported Total Revenue of $1.09 million for fiscal year 2021.
Vistagen Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $1.09M | $0.00 |
| Net Income | -$51.42M -75.1% |
-$29.36M +50.4% |
-$59.25M -24.0% |
-$47.76M -166.3% |
-$17.93M +13.7% |
-$20.77M +15.5% |
| Diluted EPS | -$1.67 -9.9% |
-$1.52 +82.1% |
-$8.51 | — | — | — |
| Total Assets | $84.34M -31.8% |
$123.65M +486.3% |
$21.09M -71.7% |
$74.64M -31.1% |
$108.28M +1775.9% |
$5.77M -58.8% |
| Cash and Equivalents | $67.13M -43.7% |
$119.17M +616.2% |
$16.64M -75.6% |
$68.14M -33.9% |
$103.11M +7508.9% |
$1.36M -89.7% |
| Stockholders Equity | $70.39M -38.4% |
$114.29M +846.1% |
$12.08M -81.3% |
$64.72M -29.6% |
$91.98M +1705.4% |
-$5.73M -181.0% |
| R&D Expense | $39.38M +96.7% |
$20.02M -54.9% |
$44.38M +25.3% |
$35.41M +196.9% |
$11.93M -10.8% |
$13.37M -21.8% |
| Operating Income | -$55.97M -69.5% |
-$33.02M +44.3% |
-$59.27M -24.0% |
-$47.78M -166.4% |
-$17.93M +13.8% |
-$20.80M +15.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2021 | $354.1K | — | +12.9% |
| Net Income | December 31, 2025 | -$18.90M | -34.1% | +2.7% |
| Diluted EPS | December 31, 2025 | -$0.45 | +2.2% | +16.7% |
| Total Assets | December 31, 2025 | $65.06M | -29.5% | -19.6% |
| Cash and Equivalents | December 31, 2025 | $47.37M | -36.6% | -24.6% |
| Long-Term Debt | December 31, 2016 | $0.00 | -100.0% | — |
| Stockholders Equity | December 31, 2025 | $50.92M | -37.2% | -23.2% |
| R&D Expense | December 31, 2025 | $14.22M | +25.8% | -10.6% |
| Operating Income | December 31, 2025 | -$19.55M | -29.3% | +2.5% |
| Shares Outstanding | June 30, 2012 | 19.64M | +28.9% | +5.0% |
- Vistagen Therapeutics, Inc. reported Total Revenue of $1.09 million for fiscal year 2021.
- Vistagen Therapeutics, Inc. reported Net Income of -$51.42 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -75.1% in Net Income compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported Diluted EPS of $1.67 per share (loss) for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -9.9% in Diluted EPS compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported Total Assets of $84.34 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -31.8% in Total Assets compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported Cash and Equivalents of $67.13 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -43.7% in Cash and Equivalents compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported Stockholders Equity of $70.39 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -38.4% in Stockholders Equity compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported R&D Expense of $39.38 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed an increase of +96.7% in R&D Expense compared to the prior fiscal year.
- Vistagen Therapeutics, Inc. reported Operating Income of -$55.97 million for fiscal year 2025.
- Vistagen Therapeutics, Inc. showed a decrease of -69.5% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: